, Volume 40, Issue 3, pp 806–817 | Cite as

5-Aminosalicylic Acid Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats by Increasing the Expression of Nur77

  • Ling-yue Sun
  • Zong-ye Cai
  • Jun Pu
  • Jian Li
  • Jie-yan ShenEmail author
  • Cheng-de YangEmail author
  • Ben He


The aim of this study is to investigate the effect of 5-aminosalicylic acid (5-ASA) on monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) in rats and its molecular mechanism. Sixty male Sprague–Dawley rats (250–300 g) were evenly randomized into six groups: control group; PAH group induced by MCT intraperitoneal injection (50 mg/kg) on day 1; and four PAH groups treated for 30 days from day 2 with 5-ASA at 50 (5-ASA-50 group), 100 (5-ASA-100 group), 150 (5-ASA-150 group), and 200 mg/kg/day (5-ASA-200 group), respectively. Body mass, weight increment, survival rates, pulmonary artery pressure (PAP), right ventricular hypertrophy index (RVHI), and the signal pathway regulated by 5-ASA were assessed. (1) Compared with the control group, the PAH group had lower body mass and weight increment, and relative to the latter, 5-ASA-treated groups had larger body mass and weight increment except for groups 5-ASA-150 and 5-ASA-200 and greater overall survival rates; (2) SPAP, DPAP, MPAP, and RVHI in 5-ASA-treated groups, except for MPAP and RVHI in 5-ASA-200 group, were lower than those in the PAH group; (3) compared with the PAH group, Nur77 expression in the pulmonary arteries of 5-ASA-treated groups was increased; and (4) expression of inflammatory mediators (NF-κB p65) was lower, while that of IκBα was higher in the pulmonary arteries of 5-ASA-treated groups and control group than that in the PAH group (all P < 0.05). 5-ASA attenuates PAH in MCT-injected rats, reducing pulmonary arterial pressures and right ventricular hypertrophy and improving survival rates, via the Nur77-NF-κB/IκBα pathway involved in modulating the pulmonary vascular remodeling.


5-aminosalicylic acid pulmonary arterial hypertension pulmonary vascular remodeling Nur77 MCT 


Compliance with Ethical Standards


This work was supported by research fund from National Natural Science Foundation of China (CN) (81570040).

Conflict of Interest

The authors declare that they have no competing interests.


  1. 1.
    Galie, N., M. Humbert, J.L. Vachiery, S. Gibbs, I. Lang, A. Torbicki, et al. 2015. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). The European Respiratory Journal 46: 903–75.CrossRefPubMedGoogle Scholar
  2. 2.
    Tuder, R.M., S.L. Archer, P. Dorfmuller, S.C. Erzurum, C. Guignabert, E. Michelakis, et al. 2013. Relevant issues in the pathology and pathobiology of pulmonary hypertension. Journal of the American College of Cardiology 62: D4–12.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Sakao, S., K. Tatsumi, and N.F. Voelkel. 2009. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respiratory Research 10: 95.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Huang, J., J.H. Wolk, M.H. Gewitz, and R. Mathew. 2010. Progressive endothelial cell damage in an inflammatory model of pulmonary hypertension. Experimental Lung Research 36: 57–66.CrossRefPubMedGoogle Scholar
  5. 5.
    Xia, L., G.S. Fu, J.X. Yang, F.R. Zhang, and X.X. Wang. 2009. Endothelial progenitor cells may inhibit apoptosis of pulmonary microvascular endothelial cells: new insights into cell therapy for pulmonary arterial hypertension. Cytotherapy 11: 492–502.CrossRefPubMedGoogle Scholar
  6. 6.
    Schwab, M., V. Reynders, S. Loitsch, Y.M. Shastri, D. Steinhilber, O. Schroder, et al. 2008. PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 29: 1407–14.CrossRefPubMedGoogle Scholar
  7. 7.
    Luciani, M.G., C. Campregher, J.M. Fortune, T.A. Kunkel, and C. Gasche. 2007. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 132: 221–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Fang, H.M., Q. Mei, J.M. Xu, and W.J. Ma. 2007. 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro. World Journal of Gastroenterology 13: 2872–7.PubMedPubMedCentralGoogle Scholar
  9. 9.
    You, B., Y.Y. Jiang, S. Chen, G. Yan, and J. Sun. 2009. The orphan nuclear receptor Nur77 suppresses endothelial cell activation through induction of IκBα expression. Circulation Research 104: 742–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Shen, L., J. Shen, J. Pu, and B. He. 2011. Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels. Cell Biochemistry and Biophysics 61: 23–31.CrossRefPubMedGoogle Scholar
  11. 11.
    Gomez-Arroyo, J.G., L. Farkas, A.A. Alhussaini, D. Farkas, D. Kraskauskas, N.F. Voelkel, et al. 2012. The monocrotaline model of pulmonary hypertension in perspective. American Journal of Physiology. Lung Cellular and Molecular Physiology 302: L363–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Maarman, G., S. Lecour, G. Butrous, F. Thienemann, and K. Sliwa. 2013. A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? Pulmonary Circulation 3: 739–56.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Harris, M.S., and G.R. Lichtenstein. 2011. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Alimentary Pharmacology & Therapeutics 33: 996–1009.CrossRefGoogle Scholar
  14. 14.
    Cui M, Cai Z, Chu S, Sun Z, Wang X, Hu L, et al. Orphan nuclear receptor Nur77 inhibits angiotensin II-induced vascular remodeling via downregulation of beta-catenin. Hypertension. 2015.Google Scholar
  15. 15.
    Kratzer, A., M. Buchebner, T. Pfeifer, T.M. Becker, G. Uray, M. Miyazaki, et al. 2009. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. Journal of Lipid Research 50: 312–26.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Pruthi, D., A. McCurley, M. Aronovitz, C. Galayda, S.A. Karumanchi, and I.Z. Jaffe. 2014. Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arteriosclerosis, Thrombosis, and Vascular Biology 34: 355–64.CrossRefPubMedGoogle Scholar
  17. 17.
    Tobiasova, Z., L. Zhang, T. Yi, L. Qin, T.D. Manes, S. Kulkarni, et al. 2011. Peroxisome proliferator-activated receptor-gamma agonists prevent in vivo remodeling of human artery induced by alloreactive T cells. Circulation 124: 196–205.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Yu, Y., Z. Cai, M. Cui, P. Nie, Z. Sun, S. Sun, et al. 2015. The orphan nuclear receptor Nur77 inhibits low shear stress-induced carotid artery remodeling in mice. International Journal of Molecular Medicine 36: 1547–55.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Cheng, Z., M. Volkers, S. Din, D. Avitabile, M. Khan, N. Gude, et al. 2011. Mitochondrial translocation of Nur77 mediates cardiomyocyte apoptosis. European Heart Journal 32: 2179–88.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hamers, A.A., M. Vos, F. Rassam, G. Marinkovic, K. Kurakula, P.J. van Gorp, et al. 2012. Bone marrow-specific deficiency of nuclear receptor Nur77 enhances atherosclerosis. Circulation Research 110: 428–38.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang, R.H., J.P. He, M.L. Su, J. Luo, M. Xu, X.D. Du, et al. 2013. The orphan receptor TR3 participates in angiotensin II-induced cardiac hypertrophy by controlling mTOR signalling. EMBO Molecular Medicine 5: 137–48.CrossRefPubMedGoogle Scholar
  22. 22.
    Arkenbout, E.K., V. de Waard, M. van Bragt, T.A. van Achterberg, J.M. Grimbergen, B. Pichon, et al. 2002. Protective function of transcription factor TR3 orphan receptor in atherogenesis: decreased lesion formation in carotid artery ligation model in TR3 transgenic mice. Circulation 106: 1530–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Chen, L.F., and W.C. Greene. 2003. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. Journal of Molecular Medicine 81: 549–57.CrossRefPubMedGoogle Scholar
  24. 24.
    Wu, K.K. 2003. Control of COX-2 and iNOS gene expressions by aspirin and salicylate. Thrombosis Research 110: 273–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Surh, Y.J., K.S. Chun, H.H. Cha, S.S. Han, Y.S. Keum, K.K. Park, et al. 2001. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutation Research 480-481: 243–68.CrossRefPubMedGoogle Scholar
  26. 26.
    Li, Y., G. Liu, D. Cai, B. Pan, Y. Lin, X. Li, et al. 2014. H2S inhibition of chemical hypoxia-induced proliferation of HPASMCs is mediated by the upregulation of COX-2/PGI2. International Journal of Molecular Medicine 33: 359–66.PubMedGoogle Scholar
  27. 27.
    Jin, C., J. Guo, X. Qiu, K. Ma, M. Xiang, X. Zhu, et al. 2014. IGF-1 induces iNOS expressionviathe p38 MAPK signal pathway in the anti-apoptotic process in pulmonary artery smooth muscle cells during PAH. Journal of Receptors and Signal Transduction 34: 325–31.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Cardiology, Ren Ji Hospital, School of MedicineShanghai Jiao Tong UniversityShanghaiChina
  2. 2.Department of CardiologyRenji Hospital (South), School of Medicine, Shanghai Jiao Tong UniversityShanghaiChina
  3. 3.Department of CardiologyThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina
  4. 4.Department of Rheumatology, Rui Jin Hospital, School of MedicineShanghai Jiao Tong UniversityShanghaiChina

Personalised recommendations